Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF in BRVO: 5 Years Experience
NCT02033031Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2012
- Primary completion
- Nov 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranibizumab and bevacizumab in macular edema and branch retinal vein occlusion (BRVO) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: visual acuity up to 6 months. Started Aug 2012; status: completed.
02
Drugs
ranibizumabbevacizumab
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT02033031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033031.